Please login to the form below

Not currently logged in
Email:
Password:

renal cell carcinoma

This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche has opted to withdraw its filing in Europe for a dual regimen for renal cell carcinoma based on checkpoint inhibitor Tecentriq and Avastin, on the grounds that the data supporting ... line use of the pair in non-small cell lung cancer (NSCLC) based

Latest news

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    Company faces pressure from competitors in renal cell carcinoma. Bristol-Myers Squibb chief executive Giovani Caforio barely mentioned the company’s finances on its third-quarter results call before launching into ... that BMS’ was the first company

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    New data presented at ESMO congress. Merck &Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, ... Pfizer when it presents the JAVELIN Renal 101 study of its

  • Merck’s Bavencio joins first-line kidney cancer face-off Merck’s Bavencio joins first-line kidney cancer face-off

    PD-L1 and TKI combination could challenge standard of care. Merck KGaA and Pfizer have staked a claim to the first-line renal cell carcinoma market, with data on a new ... The JAVELIN Renal 101 study reported at this week’s ESMO conference paired

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    In immuno-oncology, this year’s offering includes a first showing for data in first-line advanced renal cell carcinoma for Merck KGaA/Pfizer’s Bavencio (avelumab) in the JAVELIN Renal ... Merck &Co/MSD – already dominating non-small cell lung

  • NICE clears Ipsen’s Cabometyx in first-line kidney cancer NICE clears Ipsen’s Cabometyx in first-line kidney cancer

    patients with advanced renal cell carcinoma (RCC), the most common form of kidney cancer. ... Matthew Hickling, medical director of Ipsen UK &Ireland, said: “This decision is very positive news for advanced renal cell carcinoma patients that don’t

More from news
Approximately 6 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in

  • Charting a course for expansion Charting a course for expansion

    Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Deal Watch December 2015 Deal Watch December 2015

    510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics